Literature DB >> 16685216

Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study.

Fabrice Bonnet1, Michel Marre, Jean-Michel Halimi, Bénédicte Stengel, Céline Lange, Martine Laville, Jean Tichet, Beverley Balkau.   

Abstract

OBJECTIVE: Metabolic determinants of microalbuminuria remain poorly understood in non-diabetic individuals and particularly in women. We investigated in both sexes whether an elevated waist circumference (WC) or the presence of the metabolic syndrome (MetS) predict the development of elevated albuminuria at 6 years. DESIGN AND PATIENTS: We studied 2738 subjects from the DESIR cohort without microalbuminuria or diabetes at baseline and who were followed up for 6 years.
RESULTS: At 6 years, 254 individuals [9.3%; 95% confidence interval (CI) 8.2-10.4%] had developed elevated albuminuria (> or = 20 mg/l), which was significantly and positively associated with WC and blood pressure, but not with fasting glucose, lipids or body mass index in either sex. In both sexes, subjects with a high WC or with MetS at baseline were more likely to develop elevated albuminuria at 6 years compared with those with a normal WC or absence of MetS. In multivariate logistic analysis, WC as a continuous variable or a WC of 94 cm or greater for men and a WC greater than 88 cm for women were predictive of the development of elevated albuminuria, after adjusting for age, hypertension, the use of angiotensin-converting enzyme inhibitors, fibrinogen and glycaemia. MetS was a risk factor for elevated albuminuria in men (odds ratio 1.87; 95% CI 1.25-2.81), with differences according to the MetS definition.
CONCLUSION: Abdominal adiposity is related to the development of elevated albuminuria in both sexes, suggesting that the measurement of WC may improve the identification of non-diabetic individuals at risk of developing microalbuminuria and emphasizing the interest of screening for albuminuria among those with MetS.

Entities:  

Mesh:

Year:  2006        PMID: 16685216     DOI: 10.1097/01.hjh.0000226206.03560.ac

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  40 in total

Review 1.  Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.

Authors:  Rikki M Tanner; Todd M Brown; Paul Muntner
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

2.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

Review 3.  Metabolic acidosis-induced insulin resistance and cardiovascular risk.

Authors:  Gema Souto; Cristóbal Donapetry; Jesús Calviño; Maria M Adeva
Journal:  Metab Syndr Relat Disord       Date:  2011-02-25       Impact factor: 1.894

4.  Insulin resistance is associated with the development of albuminuria in Korean subjects without diabetes.

Authors:  Cheol Min Jang; Young Youl Hyun; Kyu Beck Lee; Hyang Kim
Journal:  Endocrine       Date:  2014-03-28       Impact factor: 3.633

5.  Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP).

Authors:  Andrew S Bomback; Yelena Rekhtman; Adam T Whaley-Connell; Abhijit V Kshirsagar; James R Sowers; Shu-Cheng Chen; Suying Li; Kavitha M Chinnaiyan; George L Bakris; Peter A McCullough
Journal:  Diabetes Care       Date:  2010-08-31       Impact factor: 19.112

6.  World Congress on the Insulin Resistance Syndrome, 2009: the kidney, the liver, and insulin resistance.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 19.112

7.  Involvement of visceral fat in the pathogenesis of albuminuria in patients with type 2 diabetes with early stage of nephropathy.

Authors:  Ko Hanai; Tetsuya Babazono; Izumi Nyumura; Kiwako Toya; Mari Ohta; Ryotaro Bouchi; Kumi Suzuki; Aiko Inoue; Yasuhiko Iwamoto
Journal:  Clin Exp Nephrol       Date:  2009-12-01       Impact factor: 2.801

8.  Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Authors:  E Ritz; G C Viberti; L M Ruilope; A J Rabelink; J L Izzo; S Katayama; S Ito; A Mimran; J Menne; L C Rump; A Januszewicz; H Haller
Journal:  Diabetologia       Date:  2009-10-30       Impact factor: 10.122

Review 9.  Impact of treating the metabolic syndrome on chronic kidney disease.

Authors:  Varun Agrawal; Aashish Shah; Casey Rice; Barry A Franklin; Peter A McCullough
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

10.  Albumin excretion rate in normal adolescents: relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients.

Authors:  Erin Rademacher; Michael Mauer; David R Jacobs; Blanche Chavers; Julia Steinke; Alan Sinaiko
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-09       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.